Clinical role of bisphosphonate therapy

References

• RussellRGBisphosphonates: the first 40 yearsBone201149121921555003
   PubMed Web of Science ®Google Scholar
• LiBLing ChauJFWangXLeongWFBisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapyJ Cell Biochem20111121229124221465521
   PubMed Web of Science ®Google Scholar
• CremersSPapapoulosSPharmacology of bisphosphonatesBone2011491424921281748
   PubMed Web of Science ®Google Scholar
• RoelofsAJCoxonFPEbetinoFHFluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivoJ Bone Miner Res201025360661620422624
   PubMed Web of Science ®Google Scholar
• LewieckiEMMillerPDRenal safety of intravenous bisphosphonates in the treatment of osteoporosisExpert Opin Drug Saf20076666367217967155
   PubMed Web of Science ®Google Scholar
• BlackDMSchwartzAVEnsrudKEEffects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trialJAMA2006296242927293817190893
   PubMed Web of Science ®Google Scholar
• CoxonFPThompsonKRoelofsAJEbetinoFHRogersMJVisualizing mineral binding and uptake of bisphosphonate by osteoclasts and nonresorbing cellsBone200842584886018325866
   PubMed Web of Science ®Google Scholar
• RodanGAReszkaAABisphosphonate mechanism of actionCurrent Mol Med20022571577
   PubMedGoogle Scholar
• AminDCornellSAGustafsonSKBisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesisJ Lipid Res19923311165716631464749
   PubMed Web of Science ®Google Scholar
• RussellRGWattsNBEbetinoFHRogersMJMechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacyOsteoporos Int200819673375918214569
   PubMed Web of Science ®Google Scholar
• PapapoulosSESchimmerRCChanges in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronateAnn Rheum Dis200766785385817277001
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupJAMA1999282141344135210527181
   PubMed Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDEFracture Intervention Trial Research GroupEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA199828024207720829875874
   PubMed Web of Science ®Google Scholar
• ChesnutICIIISkagAChristiansenCOral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res20041981241124915231010
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellRHORIZON Pivotal Fracture TrialOnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• ReginsterJMinneHWSorensenOHRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int2000111839110663363
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPDHip Intervention Program Study GroupEffect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupN Engl J Med2001344533334011172164
   PubMed Web of Science ®Google Scholar
• LylesKWColon-EmericCSMagazinerJSZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med2007357181799180917878149
   PubMed Web of Science ®Google Scholar
• RosenCJHochbergMCBonnickSLFosamax Actonel Comparison Trial InvestigatorsTreatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind studyJ Bone Miner Res200520114115115619680
   PubMed Web of Science ®Google Scholar
• SaagKLindsayRKriegmanABeamerEZhouWA single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral densityBone20074051238124317347063
   PubMed Web of Science ®Google Scholar
• SilvermanSLWattsNBDelmasPDLangeJLLindsayREffectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort studyOsteoporos Int2007181253417106785
   PubMed Web of Science ®Google Scholar
• HarrisSTReginsterJYHarleyCRisk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture studyBone200944575876519168160
   PubMed Web of Science ®Google Scholar
• BlackDMReidIRBoonenSThe effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)J Bone Miner Res201227224325422161728
   PubMed Web of Science ®Google Scholar
• SirisESSimonJABartonIPMcClungMRGrauerAEffects of risedronate on fracture risk in postmenopausal women with osteopeniaOsteoporos Int200819568168617968610
   PubMed Web of Science ®Google Scholar
• KanisJAOdenAJohnellOThe use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and womenOsteoporos Int2007181033104617323110
   PubMed Web of Science ®Google Scholar
• van StaaTPLeufkensHGCooperCThe epidemiology of corticosteroid- induced osteoporosis: a meta-analysisOsteoporos Int2002131077778712378366
   PubMed Web of Science ®Google Scholar
• WeinsteinRSJilkaRLParfittAMManolagasSCInhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on boneJ Clin Invest199810222742829664068
   PubMed Web of Science ®Google Scholar
• TeitelbaumSLSetonMPSaagKGShould bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?Arthritis Rheum201163232532821279986
   PubMed Web of Science ®Google Scholar
• LoCascioVBonucciEImbimboBBone loss in response to long-term glucocorticoid therapyBone Miner19908139512306553
   PubMedGoogle Scholar
• van StaaTPThe pathogenesis, epidemiology and management of glucocorticoid- induced osteoporosisCalcif Tissue Int200679312913716969593
   PubMed Web of Science ®Google Scholar
• HansenKEWilsonHAZapalowskiCFinkHAMinisolaSAdlerRAUncertainties in the prevention and treatment of glucocorticoid-induced osteoporosisJ Bone Miner Res20112691989199621721042
   PubMed Web of Science ®Google Scholar
• Van StaaTPLaanRFBartonIPCohenSReidDMCooperCBone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapyArthritis Rheum200348113224322914613287
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Ad Hoc Committee on Glucocorticoid- induced OsteoporosisRecommendations for the prevention and treatment of glucocorticoid-induced osteoporosisArthritis Rheum2001441496150311465699
   PubMed Web of Science ®Google Scholar
• GrossmanJMGordonRRanganathVKAmerican College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosisArthritis Care Res (Hoboken)201062111515152620662044
   PubMed Web of Science ®Google Scholar
• den UylDBultinkIELemsWFAdvances in glucocorticoid-induced osteoporosisCurr Rheumatol Rep201113323324021365209
   PubMed Web of Science ®Google Scholar
• PlotkinLIWeinsteinRSParfittAMRobersonPKManolagasSCBellidoTPrevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitoninJ Clin Invest1999104101363137410562298
   PubMed Web of Science ®Google Scholar
• AdachiJDSaagKGDelmasPDTwo-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trialArthritis Rheum200144120221111212161
   PubMed Web of Science ®Google Scholar
• WallachSCohenSReidDMEffects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapyCalcif Tissue Int200067427728511000340
   PubMed Web of Science ®Google Scholar
• ReidDMDevogelaerJPSaagKHORIZON investigatorsZoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trialLancet200937396711253126319362675
   PubMed Web of Science ®Google Scholar
• Fahrleitner-PammerAPiswanger-SoelknerJCPieberTRIbandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebocontrolled trialJ Bone Miner Res20092471335134419257824
   PubMed Web of Science ®Google Scholar
• SaagKGShaneEBoonenSTeriparatide or alendronate in glucocorticoid-induced osteoporosisN Engl J Med2007357202028203918003959
   PubMed Web of Science ®Google Scholar
• WeinsteinRSClinical practice. Glucocorticoid-induced bone diseaseN Engl J Med20113651627021732837
   PubMed Web of Science ®Google Scholar
• RalstonSHAlbaghaOMGenetic determinants of Paget’s disease of boneAnn N Y Acad Sci20111240536022172040
   PubMed Web of Science ®Google Scholar
• MichouLBrownJPEmerging strategies and therapies for treatment of Paget’s disease of boneDrug Des Devel Ther20115225239
   Web of Science ®Google Scholar
• SingerFRPaget disease: when to treat and when not to treatNat Rev Rheumatol20095948348919652650
   PubMed Web of Science ®Google Scholar
• SirisEWeinsteinRSAltmanRComparative study of alendronate versus etidronate for the treatment of Paget’s disease of boneJ Clin Endocrinol Metab19968139619678772558
   PubMed Web of Science ®Google Scholar
• MillerPDBrownJPSirisESHoseyniMSAxelrodDWBekkerPJA randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Paget’s Risedronate/Etidronate Study GroupAm J Med1999106551352010335722
   PubMed Web of Science ®Google Scholar
• StoneMDHawthorneABKerrDWebsterGHoskingDJTreatment of Paget’s disease with intermittent low-dose infusions of disodium pamidronate (APD)J Bone Miner Res1990512123112352075835
   PubMed Web of Science ®Google Scholar
• WalshJPWardLCStewartGOA randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget’s disease of boneBone200434474775415050907
   PubMed Web of Science ®Google Scholar
• ReidIRMillerPLylesKComparison of a single infusion of zoledronic acid with risedronate for Paget’s diseaseN Engl J Med2005353989890816135834
   PubMed Web of Science ®Google Scholar
• ReidIRLylesKSuGA single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 yearsJ Bone Miner Res20112692261227021638319
   PubMed Web of Science ®Google Scholar
• LangstonALCampbellMKFraserWDMacLennanGSSelbyPLRalstonSHPRISM Trial GroupRandomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of boneJ Bone Miner Res2010251203119580457
   PubMed Web of Science ®Google Scholar
• ReidIRNicholsonGCWeinsteinRSBiochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo-controlled trialAm J Med199610143413488873503
   PubMed Web of Science ®Google Scholar
• ColemanREClinical features of metastatic bone disease and risk of skeletal morbidityClin Cancer Res2006126243s6249s17062708
   PubMed Web of Science ®Google Scholar
• PatersonAHPowlesTJKanisJAMcCloskeyEHansonJAshleySDouble-blind controlled trial of oral clodronate in patients with bone metastases from breast cancerJ Clin Oncol199311159658418243
   PubMed Web of Science ®Google Scholar
• HultbornRGundersenSRydénSEfficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter studyActa Oncol199635Suppl 573749142971
   PubMed Web of Science ®Google Scholar
• KohnoNAogiKMinamiHZoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trialJ Clin Oncol200523153314332115738536
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J20017537738711693896
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitzerMOral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studiesBr J Cancer20049061133113715026791
   PubMed Web of Science ®Google Scholar
• BerrySWaldronTWinquistELukkaHThe use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trialsCan J Urol20061343180318816952326
   PubMedGoogle Scholar
• SaadFGleasonDMMurrayRZoledronic Acid Prostate Cancer Study GroupA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
   PubMed Web of Science ®Google Scholar
• TerposEDimopoulosMABerensonJEstablished role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone diseaseCrit Rev Oncol Hematol201177Suppl 1S13S2321353176
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMLong-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trialCancer20039881735174414534891
   PubMed Web of Science ®Google Scholar
• AaproMAbrahamssonPABodyJJGuidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panelAnn Oncol200819142043217906299
   PubMed Web of Science ®Google Scholar
• BirdJMOwenRGD’SaSHaemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma ForumGuidelines for the diagnosis and management of multiple myeloma 2011Br J Haematol20111541327521569004
   PubMed Web of Science ®Google Scholar
• BerensonJRAntitumor effects of bisphosphonates: from the laboratory to the clinicCurr Opi Support Palliat Care201153233240
   Google Scholar
• MorganGJChildJAGregoryWMNational Cancer Research Institute Haematological Oncology Clinical Studies GroupEffects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialLancet Oncol201112874375221771568
   PubMed Web of Science ®Google Scholar
• ColemanREMarshallHCameronDAZURE InvestigatorsBreast-cancer adjuvant therapy with zoledronic acidN Engl J Med2011365151396140521995387
   PubMed Web of Science ®Google Scholar
• ReidIRBisphosphonates in the treatment of osteoporosis: a review of their contribution and controversiesSkeletal Radiol20114091191119621847749
   PubMed Web of Science ®Google Scholar
• KanisJAReginsterJYKaufmanJMA reappraisal of generic bisphosphonates in osteoporosisOsteoporos Int201223121322121953472
   PubMed Web of Science ®Google Scholar
• ReidIRGambleGDMesenbrinkPLakatosPBlackDMCharacterization of and risk factors for the acute-phase response after zoledronic acidJ Clin Endocrinol Metab20109594380438720554708
   PubMed Web of Science ®Google Scholar
• BertoldoFPancheriSZenariSSerum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen- containing bisphosphonate infusionJ Bone Miner Res2010325344745420200999
   PubMed Web of Science ®Google Scholar
• KhoslaSBurrDCauleyJAmerican Society for Bone and Mineral ResearchBisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res200722101479149117663640
   PubMed Web of Science ®Google Scholar
• YoonRSHwangJSBeebeKSLong-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern?J Bone Joint Surg Br201193101289129521969423
   PubMedGoogle Scholar
• Pathophysiology of atypical femoral fractures and osteonecrosis of the jawCompston J Osteoporos Int201112221229512961
   Web of Science ®Google Scholar
• BlackDMKellyMPGenantHKFracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering CommitteeBisphosphonates and fractures of the subtrochanteric or diaphyseal femurN Engl J Med2010362191761177120335571
   PubMed Web of Science ®Google Scholar
• Park-WyllieLYMamdaniMMJuurlinkDNBisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older womenJAMA2011305878378921343577
   PubMed Web of Science ®Google Scholar
• CummingsSRSchwartzAVBlackDMAlendronate and atrial fibrillationN Engl J Med2007356181895189617476024
   PubMed Web of Science ®Google Scholar
• CardwellCRAbnetCCCantwellMMMurrayLJExposure to oral bisphosphonates and risk of esophageal cancerJAMA2010304665766320699457
   PubMed Web of Science ®Google Scholar
• GreenJCzannerGReevesGWatsonJWiseLBeralVOral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohortBMJ2010341c444420813820
   PubMed Web of Science ®Google Scholar
• KilickapSOzdamarYAltundagMKDizdarOA case report: zoledronic acid-induced anterior uveitisMed Oncol200825223824018488162
   PubMed Web of Science ®Google Scholar
• PetersonJDBedrossianEHJrBisphosphonate-associated orbital inflammation – a case report and reviewOrbit2012431211912322489855
   PubMedGoogle Scholar
• FrenchDDMargoCEPostmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohortRetina200828688989318536608
   PubMed Web of Science ®Google Scholar
• EtminanMForooghianFMaberleyDInflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort studyCMAJ2012Epub April2
   Google Scholar
• NancollasGHTangRPhippsRJNovel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatiteBone200638561762716046206
   PubMed Web of Science ®Google Scholar
• SatoMGrasserWEndoNBisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructureJ Clin Invest1991886209521051661297
   PubMed Web of Science ®Google Scholar